LEGN (Legend Biotech) Stock Analysis - AI Report

Legend Biotech (LEGN) is a publicly traded Healthcare sector company. As of May 21, 2026, LEGN trades at $27.70 with a market cap of $5.01B and a P/E ratio of 0.00. LEGN moved +4.36% today. Year to date, LEGN is +38.45%; over the trailing twelve months it is -6.48%. Its 52-week range spans $16.24 to $51.77. Analyst consensus is strong buy with an average price target of $55.90. Rallies surfaces LEGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on LEGN?

Rallies AI research for LEGN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

LEGN Key Metrics

Key financial metrics for LEGN
MetricValue
Price$27.70
Market Cap$5.01B
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$51.77
52-Week Low$16.24
Volume1.05K
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest LEGN News

Recent LEGN Insider Trades

  • Huang Ying sold 9.94K (~$87.14K) on Mar 25, 2026.

LEGN Analyst Consensus

11 analysts cover LEGN: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $55.90.

Common questions about LEGN

What is the AI research view on LEGN?
Rallies AI research for LEGN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for LEGN?
Rallies AI research for LEGN combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is LEGN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LEGN. It does not provide personalized investment advice.
LEGN

Legend Biotech